Phibro Animal Health Corporation (PAHC)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.46B
Last updated: Nov 17, 2026 at 11:04 AM ET
Phibro Animal Health Corporation (PAHC) Earnings: Report Dates and Results
Phibro Animal Health (PAHC) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Phibro Animal Health reported EPS of $0.79, in line with the $0.79 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PAHC has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.0% above the $0.87 reported for the quarter ended Dec 31, 2025.
PAHC Earnings Call
The latest PAHC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PAHC beat 24, missed 14 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $386.77M, up 6.3% from $363.89M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.79 | $0.79 | $0.76 - $0.81 | 0.00% | In line | +8.2% | 3 | 0 up, 1 down | Nov 4, 2026 | $386.77M |
| Jun 30, 2026 | $0.85 | $0.72 | $0.68 - $0.75 | +18.06% | Beat | +49.1% | 4 | 0 up, 1 down | Aug 26, 2026 | $396.75M |
| Mar 31, 2026 | $0.76 | $0.71 | $0.70 - $0.73 | +7.04% | Beat | +20.6% | 5 | 2 up, 0 down | May 6, 2026 | $383.54M |
| Dec 31, 2025 | $0.87 | $0.67 | $0.62 - $0.72 | +29.85% | Beat | +61.1% | 4 | 1 up, 1 down | Feb 4, 2026 | $373.91M |
| Sep 30, 2025 | $0.73 | $0.59 | $0.52 - $0.68 | +23.73% | Beat | +108.6% | 3 | 1 up, 0 down | Nov 5, 2025 | $363.89M |
| Jun 30, 2025 | $0.57 | $0.52 | $0.50 - $0.54 | +9.62% | Beat | +39.0% | 3 | 0 up, 3 down | Aug 27, 2025 | $378.70M |
| Mar 31, 2025 | $0.63 | $0.52 | $0.49 - $0.56 | +21.15% | Beat | +103.2% | 3 | 0 up, 2 down | May 7, 2025 | $347.82M |
| Dec 31, 2024 | $0.54 | $0.45 | $0.40 - $0.48 | +20.00% | Beat | +63.6% | 3 | 1 up, 1 down | Feb 5, 2025 | $309.26M |
| Sep 30, 2024 | $0.35 | $0.25 | $0.20 - $0.30 | +40.00% | Beat | +150.0% | 4 | 1 up, 0 down | Nov 7, 2024 | $260.43M |
| Jun 30, 2024 | $0.41 | $0.33 | $0.33 - $0.34 | +24.24% | Beat | +7.9% | 3 | 0 up, 0 down | Aug 28, 2024 | $273.16M |
| Mar 31, 2024 | $0.31 | $0.29 | $0.29 - $0.29 | +6.90% | Beat | +6.9% | 3 | 0 up, 0 down | May 8, 2024 | $263.22M |
| Dec 31, 2023 | $0.33 | $0.28 | $0.24 - $0.32 | +17.86% | Beat | -2.9% | 4 | 0 up, 0 down | Feb 7, 2024 | $249.94M |
| Sep 30, 2023 | $0.14 | $0.23 | $0.20 - $0.28 | -39.13% | Miss | -33.3% | 3 | 0 up, 0 down | Nov 8, 2023 | $231.35M |
| Jun 30, 2023 | $0.38 | $0.38 | $0.37 - $0.42 | 0.00% | In line | +5.6% | 4 | 0 up, 0 down | Aug 30, 2023 | $255.05M |
| Mar 31, 2023 | $0.29 | $0.34 | $0.31 - $0.35 | -14.71% | Miss | -12.1% | 4 | 0 up, 0 down | May 3, 2023 | $245.67M |
| Dec 31, 2022 | $0.34 | $0.30 | $0.24 - $0.35 | +13.33% | Beat | -8.1% | 4 | 0 up, 0 down | Feb 8, 2023 | $244.65M |
| Sep 30, 2022 | $0.21 | $0.27 | $0.24 - $0.30 | -22.22% | Miss | -16.0% | 3 | 0 up, 0 down | Nov 9, 2022 | $232.52M |
| Jun 30, 2022 | $0.36 | $0.38 | $0.35 - $0.42 | -5.26% | Miss | +12.5% | 3 | 1 up, 0 down | Aug 24, 2022 | $255.26M |
| Mar 31, 2022 | $0.33 | $0.35 | $0.34 - $0.36 | -5.71% | Miss | -2.9% | 3 | 0 up, 0 down | May 4, 2022 | $239.62M |
| Dec 31, 2021 | $0.37 | $0.33 | $0.32 - $0.34 | +12.12% | Beat | +8.8% | 3 | 0 up, 0 down | Feb 9, 2022 | $232.71M |
| Sep 30, 2021 | $0.25 | $0.29 | $0.25 - $0.35 | -13.79% | Miss | -7.4% | 3 | N/A | Nov 2, 2021 | $214.66M |
| Jun 30, 2021 | $0.32 | $0.31 | $0.30 - $0.32 | +3.23% | Beat | +88.2% | 4 | N/A | Aug 25, 2021 | $220.28M |
| Mar 31, 2021 | $0.34 | $0.32 | $0.32 - $0.39 | +6.25% | Beat | -10.5% | 5 | N/A | May 6, 2021 | $211.73M |
| Dec 31, 2020 | $0.34 | $0.28 | $0.23 - $0.29 | +21.43% | Beat | 0.0% | 5 | N/A | Feb 3, 2021 | $206.15M |
| Sep 30, 2020 | $0.27 | $0.23 | $0.19 - $0.36 | +17.39% | Beat | +42.1% | 5 | N/A | Nov 4, 2020 | $195.19M |
| Jun 30, 2020 | $0.17 | $0.22 | $0.15 - $0.28 | -22.73% | Miss | -48.5% | 5 | N/A | Aug 26, 2020 | $185.88M |
| Mar 31, 2020 | $0.38 | $0.34 | $0.30 - $0.38 | +11.76% | Beat | -2.6% | 5 | N/A | May 7, 2020 | $210.74M |
| Dec 31, 2019 | $0.34 | $0.29 | $0.27 - $0.30 | +17.24% | Beat | -17.1% | 5 | N/A | Feb 3, 2020 | $214.01M |
| Sep 30, 2019 | $0.19 | $0.24 | $0.19 - $0.28 | -20.83% | Miss | -51.3% | 5 | N/A | Nov 4, 2019 | $189.72M |
| Jun 30, 2019 | $0.33 | $0.36 | $0.33 - $0.42 | -8.33% | Miss | -28.3% | 5 | N/A | Aug 27, 2019 | $203.88M |
| Mar 31, 2019 | $0.39 | $0.43 | $0.43 - $0.43 | -9.30% | Miss | -18.7% | 3 | N/A | May 6, 2019 | $205.74M |
| Dec 31, 2018 | $0.41 | $0.43 | $0.42 - $0.44 | -4.65% | Miss | +17.1% | 3 | N/A | Feb 6, 2019 | $218.22M |
| Sep 30, 2018 | $0.39 | $0.41 | $0.38 - $0.44 | -4.88% | Miss | +2.6% | 3 | N/A | Nov 6, 2018 | $200.15M |
| Jun 30, 2018 | $0.46 | $0.42 | $0.37 - $0.44 | +9.52% | Beat | +17.9% | 4 | N/A | Aug 27, 2018 | $211.79M |
| Mar 31, 2018 | $0.48 | $0.44 | $0.43 - $0.44 | +9.09% | Beat | +14.3% | 3 | N/A | May 7, 2018 | $208.91M |
| Dec 31, 2017 | $0.35 | $0.39 | $0.35 - $0.41 | -10.26% | Miss | +2.9% | 5 | N/A | Feb 5, 2018 | $205.88M |
| Sep 30, 2017 | $0.38 | $0.37 | $0.36 - $0.39 | +2.70% | Beat | +5.6% | 5 | N/A | Nov 6, 2017 | $193.41M |
| Jun 30, 2017 | $0.39 | $0.33 | $0.33 - $0.33 | +18.18% | Beat | -2.5% | 4 | N/A | Aug 30, 2017 | $194.84M |
| Mar 31, 2017 | $0.42 | $0.34 | N/A | +23.53% | Beat | +10.5% | N/A | N/A | May 8, 2017 | $189.86M |
| Dec 31, 2016 | $0.34 | $0.35 | N/A | -2.86% | Miss | -12.8% | N/A | N/A | Feb 6, 2017 | $191.60M |
Annual EPS
EPS for the fiscal year ended Jun 30, 2026 was $3.21, up 53.6% from the year before. It was $1.51 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Jun 30, 2026 | $3.21 | +53.6% |
| Jun 30, 2025 | $2.09 | +75.6% |
| Jun 30, 2024 | $1.19 | N/A |
| Jun 30, 2023 | $1.22 | -6.9% |
| Jun 30, 2022 | $1.31 | N/A |
| Jun 30, 2021 | $1.27 | +17.6% |
| Jun 30, 2020 | $1.08 | -28.9% |
| Jun 30, 2019 | $1.52 | -9.0% |
| Jun 30, 2018 | $1.67 | +10.6% |
| Jun 30, 2017 | $1.51 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,700 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,742 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,947 | 9 | |
| 2026Q1 | Mar 31, 2026 | 3,166 | 9 | |
| 2025Q4 | Dec 31, 2025 | 4,175 | 9 | |
| 2025Q3 | Sep 30, 2025 | 3,327 | 6 | |
| 2025Q2 | Jun 30, 2025 | 3,888 | 8 | |
| 2025Q1 | Mar 31, 2025 | 3,617 | 9 | |
| 2024Q4 | Dec 31, 2024 | 3,155 | 6 |
2026Q3 Earnings Call
Opening remarks
Regina Conference Operator Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation Third Quarter 2026 Earnings Conference Call. I will now turn the conference over to Glenn David, Chief Financial Officer. Please go ahead.
Glenn David Chief Financial Officer Thank you, Regina. Good day, and welcome to the Phibro Animal Health Corporation Earnings Call for our fiscal third quarter ended March 31, 2026. My name is Glenn David, and I'm the Chief Financial Officer of Phibro Animal Health Corporation. I am joined on today's call by Jack Bendheim, Phibro's Chairman, President and Chief Executive Officer; Daniel Bendheim, Director and Executive Vice President of Corporate Strategy and, as previously announced, our CEO designate; and Larry Miller, Chief Operating Officer. Today, we will cover financial performance for our third quarter and provide updated financial guidance for our fiscal year ending June 30, 2026. At the conclusion of our remarks, we will open the lines for your questions. I would like to remind you that we are providing a simultaneous webcast of this call on our website, pahc.com. Also, on the Investors section of our website, you will find copies of the earnings press release and quarterly Form 10-Q as well as the transcript and slides discussed and presented on this call. Our remarks today will include forward-looking statements, and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements section in our earnings press release. Our remarks include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or U.S. GAAP. I refer you to the non-GAAP financial information section in our earnings press release for a discussion of these measures. Reconciliations of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition-related items, unusual, nonoperational or nonrecurring items, including stock-based compensation. Other income expense is separately reported in the consolidated statement of operations, including foreign currency losses, gains and income taxes related to pretax income adjustments and unusual or nonrecurring income tax items. Now let me introduce our Chairman, President and Chief Executive Officer, Jack Bendheim, to share his opening remarks. Jack?
Jack Bendheim Chairman, President and Chief Executive Officer Thanks, Glenn, and good morning, everyone. We had a strong third quarter. Net sales increased 10% to $383 million and adjusted EBITDA increased 11% to $60 million.
Frequently Asked Questions About PAHC
When is Phibro Animal Health's next earnings date?
Phibro Animal Health's next earnings report is expected for Feb 2, 2027.
Did PAHC beat earnings estimates last quarter?
Phibro Animal Health reported EPS of $0.79 for the quarter ended Sep 30, 2026, in line with the $0.79 estimate.
What EPS do analysts expect from PAHC next quarter?
The consensus EPS estimate for Phibro Animal Health for the quarter ending Dec 31, 2026 is $0.94 from 2 analysts, with estimates from $0.91 to $0.97.
How often does PAHC beat earnings estimates?
Phibro Animal Health beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +16.18%.
PAHC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors